Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

August 1, 2024

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
July 24, 2024

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
July 9, 2024

Immunic Appoints Jason Tardio as Chief Operating Officer and President
May 28, 2024

Immunic to Participate in Industry and Scientific Conferences in June
May 8, 2024

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 6, 2024

Immunic to Participate in Investor and Scientific Conferences in May
May 1, 2024

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
April 30, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
April 4, 2024

Immunic to Host MS R&D Day and Participate in Investor Conferences in April
March 20, 2024

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Show per page